ReviewPrzeglad gastroenterologiczny2026
The gut-liver axis in cirrhosis: bacterial translocation, immune dysregulation, and the impact of microbiota in diverse aetiologies.
Review in Przeglad gastroenterologiczny, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cirrhosis is the final common pathway of many chronic liver diseases and is associated with significant morbidity and mortality. Recent advances have revealed that the gut microbiota and the phenomenon of bacterial translocation play a fundamental role in the progression and complications of cirrhosis. This includes the development of hepatic encephalopathy, systemic inflammation, renal dysfunction, and sarcopenia. This comprehensive review explains the gut-liver axis in cirrhosis, the mechanisms and clinical consequences of bacterial translocation, the features of dysbiosis across different aetiologies such as metabolic dysfunction-associated fatty liver disease, and the immune dysregulation characteristic of cirrhotic patients. We also highlight how these processes contribute to major complications such as hepatic encephalopathy and sarcopenia, and we discuss emerging therapeutic opportunities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.